AAAAAA
Results:
1-24
|
Results: 24
Authors:
Stewart, S
Jones, D
Day, CP
Citation: S. Stewart et al., Alcoholic liver disease: new insights into mechanisms and preventative strategies, TRENDS MO M, 7(9), 2001, pp. 408-413
Authors:
Stewart, SF
Day, CP
Citation: Sf. Stewart et Cp. Day, Liver disorder and the HFE locus, QJM-MON J A, 94(9), 2001, pp. 453-456
Authors:
Daly, AK
Day, CP
Citation: Ak. Daly et Cp. Day, Candidate gene case-control association studies: advantages and potential pitfalls, BR J CL PH, 52(5), 2001, pp. 489-499
Authors:
Day, CP
Citation: Cp. Day, Apoptosis in alcoholic hepatitis: a novel therapeutic target?, J HEPATOL, 34(2), 2001, pp. 330-333
Authors:
Aithal, GP
Craggs, A
Day, CP
Welfare, M
Daly, AK
Mansfield, JC
Hudson, M
Citation: Gp. Aithal et al., Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease, DIG DIS SCI, 46(7), 2001, pp. 1520-1525
Authors:
Stewart, SF
Hudson, M
Talbot, D
Manas, D
Day, CP
Citation: Sf. Stewart et al., Mycophenolate mofetil monotherapy in liver transplantation, LANCET, 357(9256), 2001, pp. 609-610
Authors:
Day, CP
Citation: Cp. Day, Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis, GUT, 49(6), 2001, pp. 750-751
Authors:
Mitchell, SA
Grove, J
Spurkland, A
Boberg, KM
Fleming, KA
Day, CP
Schrumpf, E
Chapman, RW
Citation: Sa. Mitchell et al., Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis, GUT, 49(2), 2001, pp. 288-294
Authors:
Aithal, GP
Day, CP
Leathart, JBS
Daly, AK
Citation: Gp. Aithal et al., Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis, PHARMACOGEN, 10(6), 2000, pp. 511-518
Authors:
Reeves, HL
Thompson, MG
Dack, CL
Burt, AD
Day, CP
Citation: Hl. Reeves et al., The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells, HEPATOLOGY, 31(1), 2000, pp. 95-100
Authors:
Aithal, GP
Rawlins, MD
Day, CP
Citation: Gp. Aithal et al., Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions, J HEPATOL, 33(6), 2000, pp. 949-952
Authors:
Reeves, HL
Dack, CL
Peak, M
Burt, AD
Day, CP
Citation: Hl. Reeves et al., Stress-activated protein kinases in the activation of rat hepatic stellatecells in culture, J HEPATOL, 32(3), 2000, pp. 465-472
Authors:
Day, CP
Citation: Cp. Day, Who gets alcoholic liver disease: nature or nurture?, J ROY COL P, 34(6), 2000, pp. 557-562
Authors:
Grove, J
Daly, AK
Bassendine, MF
Gilvarry, E
Day, CP
Citation: J. Grove et al., Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease, GUT, 46(4), 2000, pp. 540-545
Authors:
Aithal, GP
Rawlins, MD
Day, CP
Citation: Gp. Aithal et al., Accuracy of hepatic adverse drug reaction reporting in one English health region, BR MED J, 319(7224), 1999, pp. 1541-1541
Authors:
Dixon, M
Agius, L
Yeaman, SJ
Day, CP
Citation: M. Dixon et al., Inhibition of rat hepatocyte proliferation by transforming growth factor beta and glucagon is associated with inhibition of ERK2 and p70 S6 kinase, HEPATOLOGY, 29(5), 1999, pp. 1418-1424
Authors:
Jones, DEJ
Watt, FE
Grove, J
Newton, JL
Daly, AK
Gregory, WL
Day, CP
James, OFW
Bassendine, MF
Citation: Dej. Jones et al., Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis, J HEPATOL, 30(2), 1999, pp. 232-236
Authors:
James, OFW
Day, CP
Citation: Ofw. James et Cp. Day, Non-alcoholic steatohepatitis - Reply, LANCET, 354(9186), 1999, pp. 1299-1299
Authors:
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
Citation: Gp. Aithal et al., Warfarin dose requirement and CYP2C9 polymorphisms - Reply, LANCET, 353(9168), 1999, pp. 1972-1973
Authors:
Aithal, GP
Day, CP
Kesteven, PJL
Daly, AK
Citation: Gp. Aithal et al., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, LANCET, 353(9154), 1999, pp. 717-719
Authors:
Aithal, PG
Day, CP
Citation: Pg. Aithal et Cp. Day, The natural history of histologically proved drug induced liver disease, GUT, 44(5), 1999, pp. 731-735
Authors:
Day, CP
Citation: Cp. Day, HFE and alcoholic liver disease - Reply, GUT, 44(3), 1999, pp. 440-440
Authors:
Reeves, HL
Francis, RM
Manas, DM
Hudson, M
Day, CP
Citation: Hl. Reeves et al., Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation, LIVER TR S, 4(5), 1998, pp. 404-409
Authors:
Fairbrother, KS
Grove, J
de Waziers, I
Steimel, DT
Day, CP
Crespi, CL
Daly, AK
Citation: Ks. Fairbrother et al., Detection and characterization of novel polymorphisms in the CYP2E1 gene, PHARMACOGEN, 8(6), 1998, pp. 543-552
Risultati:
1-24
|